CRSPCRISPR Therapeutics AG
$53.41-14% 1Y
$53.41
$44.3452 weeks$76.78
Latest close: back above its 200-day averageOct 9, 2026what changed →
CRSP in its own filings
Nothing in CRSP's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
228
Events found in the filings · across 865 filings · the record starts in 2016
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 3, 2026
Most recent filing · Form 10-Q
- Record starts
- Jun 13, 2016
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- SEC comment-letter activity19 occurrences
- 2022-07-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jun 4, 2026Approval of CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan On June 4, 2026, at the 2026 Annual General Meeting of Shareholders (the “Annual Meeting”), the shareholders of CRISPR Therapeutics AG (the “Company”) approved the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan (the “2026 Plan”)Director or officer change · Form 8-K
- May 4, 2026CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results.Earnings release · press release
- Mar 16, 2026On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an …Material agreement entered · Form 8-K
- Mar 11, 2026On March 10, 2026, CRISPR Therapeutics AG (the “Company”) issued a press release announcing that it had commenced a private offering, subject to market conditions and other factors, of $350.0 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) to persons reasonably believed to be …Other event · Form 8-K
- Feb 12, 2026CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
- Jan 12, 2026On January 12, 2026, CRISPR Therapeutics AG (the “Company”) issued a press release highlighting, among other things, selected updates related to its wholly-owned cardiovascular, autoimmune, immuno-oncology and regenerative medicine programs: • The Company continues to advance a diversified portfolio of in vivo gene …Other event · Form 8-K
- Oct 15, 2025As previously reported, on August 30, 2019, CRISPR Therapeutics AG (the “Company”) entered into an Open Market Sale Agreement TM (the “Agreement”) with Jefferies LLC (“Jefferies”), under which the Company may offer and sell, from time to time at its sole discretion through Jefferies, as its sales agent, its common …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Biotechnology
The closest names by size in the same industry